GlassScriptPhysician profile
Smriti Goyal
NPI 1730127440
$2,827.29
in general payments reported to CMS, 2019-2025
19 companies · $329 in 2025
The $329 reported for 2025 was more than what 85% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $139 · 2021: $888 · 2022: $336 · 2023: $479 · 2024: $307 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,381.34 | 2019-2024 | Xarelto |
| Pfizer INC. | $234.83 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.91 | 2020-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $153.94 | 2021-2024 | Ultomiris |
| Gt Medical Technologies, INC | $140.00 | 2023 | Gammatile |
| Astrazeneca Pharmaceuticals LP | $105.97 | 2019-2025 | Lokelma |
| Janssen Scientific Affairs, LLC | $102.10 | 2023 | Xarelto |
| Smith+Nephew, INC. | $89.72 | 2025 | Collagenase Santyl |
| Genzyme Corporation | $69.33 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.52 | 2021-2025 | Lifevest |
| Amgen INC. | $45.19 | 2024-2025 | Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.96 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $40.44 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $40.21 | 2021-2025 | Eliquis |
| Gilead Sciences, INC. | $39.39 | 2023-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.42 | 2025 | General - Therapies |
| Melinta Therapeutics, LLC | $33.74 | 2024 | Orbactiv |
| La Jolla Pharmaceutical Company | $15.10 | 2023 | Xerava |
| Novartis Pharmaceuticals Corporation | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smriti Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.